Normally present in only trace amounts in plasma, dietary plant sterols (phytosterols) are largely excreted from the body and very poorly reabsorbed. In patients diagnosed with sitosterolemia, plant dietetic sterols are not optimally excreted, resulting in a 30-100 fold increase in plasma sterol levels. Inability to process sterols ultimately results in tissue deposition and potential xanthoma formation. [2] [3] [4] Because of shared clinical features, when hypercholesterolemia is profound, sitosterolemia may be erroneously diagnosed as homozygous familial hypercholesterolemia, also referred to as pseudohomozygous type II hypercholesterolemia (PHT2HC), based on cholesterol levels and xanthomas. However, these conditions have very distinct etiologies, are associated with variable atherogenic risk, and require divergent clinical management, emphasizing the need for accurate diagnosis. Diagnosis of sitosterolemia in children presenting with elevated cholesterol and early xanthomatosis is critical, since the low fat/low cholesterol diet likely to be prescribed in the context of a hypercholesterolemia diagnosis is high in vegetable oil content, which could exacerbate the metabolic derangements associated with sitosterolemia. We report a pediatric patiend with suspected (PHT2HC) who was eventually correctly diagnosed with sitosterolemia that was confirmed by biochemical analysis demonstrating elevated plasma levels of phytosterols. present. 5 The patient was generally in good health having developed normally, with height and weight at the 50 th and 25 th percentile, respectively, for European girls. Outside of a maternal grandfather who had undergone coronary bypass surgery at age 55, no famial history of atherosclerotic disease or premature death was noted.
The child showed mild microcytic anemia (blood hemoglobin 1.6 mmol/L, hematocrit 34%) with signs of latent iron deficiency (plasma iron 40 µmol/L, transferrin 2.6 g/L, ferritin 17 µg/L), with otherwise unremarkable laboratory evaluations at her initial evaluation (figure 1B) including platelet count (253 x 10 9 /L), blood leucocytes, renal, liver, and thyroid function parameters, blood glucose, hemoglobin A1c, coagulation parameters, plasma triglycerides, plasma homocystine, and urinalysis. Electrocardiogram and echocardiography were normal.
Lipoprotein electrophoresis showed total plasma cholesterol levels of 290 mg/dL (7.5 mmol/L), Autosomal recessive LDL adaptor protein (LDLRQP1) mutation is also causal for familial hypercholesterolemia. 13 The condition is typically characterized by abnormally elevated serum LDL cholesterol levels, a family history of hypercholesterolemia, tendon xanthoma formation, high risk for premature atheroma formation, and a subset may exhibit cornal arcus. 5 Homozygous or compound heterozygous mutations in LDLR result in the particularly severe form of familial hypercholesterolemia, known as homozygous familial (or type II) hypercholesterolemia, in which hypercholesterolemia is profound, and premature cardiovascular disease can present in childhood.
Therapy has included lipid lowering therapy (statins with or without ezetibmibe, a cholesterol absorption inhibitor, 14 lipoprotein apheresis, plant sterol supplementation, 15 or new classes of agents including lomitapide and mipomersen.
13
PHT2HC was first first described in 1974 7 following unsuccessful identification of other potential causes for hypercholesterolemia in a case of profound hypercholesterolemia not caused by LDLR defect. Cases presenting with this condition, whose etiology remains undefined, also exhibited remarkably elevated cholesterol levels with normal triglyceride levels and presentation of cutaneous and tendon xanthomas during childhood but lacked familial history of hypercholesterolemia in first degree relatives. [7] [8] [9] Whereas these patients were at high risk for early atherogenesis, significant reduction in serum cholesterol was achieved in response to dietary therapy incorporating a low fat, low cholesterol diet in combination with administration of bile acid resin. [7] [8] [9] Further, patients with PHT2HC exhibit normal LDL receptor function. 16 Based on genetic analysis, Rees et al 17 found that large platelet size is a characteristic hematological presentation in phytosterolemia, suggesting that the platelet size should be noted in patients with hypercholesterolemia.
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This condition also features tendon xanthoma formation as a clinical presentation and is typically associated with normal or only moderately elevated plasma cholesterol concentrations, with cholesterol levels responsive to dietary intervention, consistent with findings of reduced HMG-CoA reductase activity in sitosterolemia, 3, 18 and therefore overlap with some criteria for PHT2HC. However, an additional rare documented presentation of sitosterolemia includes profound hypercholesterolemia and xanthomas in childhood. [19] [20] [21] [22] These patients with sitosterolemia may also exhibit stomatocytosis and macrothrombocytopenia, as described in the present case. Further, these patients do not have family histories of of hypercholesterolemia (unless coincidental), and like our index patient, exhibit normal LDL receptor function in in vitro assays. 6, 16 The genetic underpinnings of sitoserolemia were elucidated by Berge et al, 23 Lu et al, 24 and Lee et al, 25 following mapping of causal genetic mutations in two highly homologous genes in the STSL locus on chromosome 2p21. Specifically, mutations in ABCG5 or ABCG8 impede dimerization of the gene expression products, sterolin 1 or 2, respectively, resulting in prevention of expression at the cellular lumen of canalicular hepatocytes and intestinal brush border enterocytes, where they normally function as efflux pumps to extrude phytosterols into bile for eventual incorporation into chylomicrons and subsequent elimination. 26, 27 Diagnosis is validated via plasma sterol profiling by gas chromatography to determine levels of sitosterol, campesterol and stigmasterol. [2] [3] [4] Only few case reports in patients where sitosterolemia was recognized as a cause of PHT2HC have been previously reported including three Japanese reports of two unrelated subjects and one pair of sisters, [19] [20] [21] and one report on two unrelated Chinese patients, 22 with a history of xanthoma
Rare sitosterolemia case presentation Page 10 Copyright © 2016 Marshfield Clinic Health System development during childhood. Lee et al, 28 in 2001, were the first to demonstrate that subjects identified as pseudohomzygous familial hypercholesterolemia had sitsterolemia. Another potential case in a black child with a profile similar to our case was reported as sitosterolemia. 11 In the present case, we did not have the opportunity to carry out DNA mutation analysis for ABCG5 or ABCG8 mutations. In addition, ezetimibe was not prescribed in this patient, although that has become a standard therapy since the time this patient was diagnosed, and its use can ameliorate platelet defects. 30 In summary, it is important to consider a differential diagnosis in children presenting with profound hypercholesterolemia with a probable familial hypercholesterolemia diagnosis. Further, cases in which familial hypercholesterolemia is not confirmed, who may be labelled as PHT2HC, should be screened for sitosterolemia despite its rarity. Accurate diagnosis is critical to appropriate dietary management. Standard dietary therapy for hypercholesterolemia is not therapeutic in patients with undiagnosed sitosterolemia presenting with clinical features consistent with PHT2HC. Whereas plasma cholesterol was reduced in our patient by dietary measures, reduction in plasma plant sterols levels proved resistant to low fat dietary therapy alone and only improved with cholestyramine administration. Currently, clinical management with inclusion of ezetimibe as a therapeutic adjunct is recommended as a safe, effective cholesterol lowering agent in the context of long-term use. 31, 32 Ezetimibe inhibits NPC1L1 sterol resorption at the level of the intestinal lumen. 33 Based on our experience and only rare reports in the historical literature, we underline the necessity of recognizing PHT2HC, especially in pediatric patients, and recommend testing patients with 
